Moderna trims top end of full-year forecast on weak COVID vaccine sales

Core Viewpoint - Moderna has reduced the upper limit of its 2025 revenue forecast by $200 million due to lower-than-expected sales of its COVID-19 vaccine in the U.S. market, as access to the vaccine has been a challenge for Americans [1] Company Summary - Moderna's adjustment in revenue forecast reflects a significant impact from the sales performance of its COVID-19 vaccine [1] - The company is facing challenges related to vaccine accessibility, which has contributed to the weaker sales figures [1]